AstraZeneca, Daiichi beat Gilead to first-line TNBC with FDA nod for Datroway

22nd May 2026 Uncategorised 0

A three-way battle among TROP2 ADCs in first-line triple-negative breast cancer is forming as AstraZeneca and Daiichi Sankyo’s Datroway became the first to cross the FDA’s finish line.

More: AstraZeneca, Daiichi beat Gilead to first-line TNBC with FDA nod for Datroway
Source: fierce